A drug approved for adults and pediatric patients with post transplant cytomegalovirus infection that doesn’t respond to available antiviral treatment.
Tradename Livtencity.
It blocks viral replication by inhibiting the human CMV enzyme pUL 97.
CMV is a common infection following stem cell or organ transplant and this is associated with increased risk for complications and death.
Cytomegalovirus infections that are resistant or do not respond to available drugs are of greater concern.
It lowers plasma CMV DNA below measurable levels compared to other agents.
Common adverse effects: taste disturbance, nausea, diarrhea, vomiting, and fatigue.
The drug may reduce the activity of gangiclovir and valganciclovir and they shouldn’t be used together.